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Abstract: Di(2-ethylhexyl) phthalate (DEHP) is widely used as a plasticizer in consumer products.
People are continuously exposed to DEHP through ingestion, inhalation and dermal absorption.
From epidemiological studies, DEHP has been shown to associate with various adverse health
effects, such as reproductive abnormalities and metabolic diseases. Health concerns have been
raised regarding DEHP exposures; therefore, relevant risk assessment has become necessary through
toxicological testing of DEHP. In the past 10 years, an increasing number of DEHP toxicity studies
have been using zebrafish embryos as an in vivo model due to their high fecundity, rapid embryonic
development as well as optical transparency, which have now been established as an alternative of
the more conventional rodent model. The aim of the present paper is to review the effects of acute
(from embryo stage to ≤1 week) and chronic (from embryo stage to >1 week) DEHP exposures
on zebrafish, which start from the embryonic stage, and to analyze acute and potential long-term
effects induced by acute exposure and effects induced by chronic exposure of DEHP upon subjecting
to exposures, starting from the embryonic stage to different developmental stages, with a view to
facilitate risk assessments on DEHP exposures.
Keywords: phthalate; di(2-ethylhexyl) phthalate (DEHP); mono-2-ethylhexyl phthalate (MEHP);
zebrafish embryo; toxic effect
1. Introduction
Phthalates have been widely applied as plasticizers to enhance the flexibility of plastic
in consumer products, such as toys, food containers, cosmetics, personal care products
and furniture as well as medical devices [1], but at the same time have been recognized as
endocrine disrupting chemicals (EDCs) [2]. Nowadays, people are pervasively exposed to
phthalates through ingestion, inhalation and dermal absorption [1] since phthalates can
easily migrate into the environment with time and use as they are not covalently bound to
plastics [3–5].
Ten widely used phthalates were summarized by Wang et al., including dimethyl
phthalate (DMP), diethyl phthalate (DEP), dibutyl phthalate (DBP), diisobutyl phthalate
(DIBP), butyl benzyl phthalate (BBzP), dicyclohexyl phthalate (DCHP), di(2-ethylhexyl) ph-
thalate (DEHP), di-n-octyl phthalate (DnOP), diisononyl phthalate (DINP) and diisodecyl
phthalate (DIDP), the structures of which are depicted in Figure 1 [6].
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Figure 1. Ten widely used phthalates as summarized by Wang et al. [6]. 
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Zebrafish has become a popular vertebrate model widely applied in toxicological
studies due to its high fecundity, rapid embryonic development as well as optical trans-
parency [28,29]. Moreover, development of zebrafish and mammals are similar. Impor-
tantly, the genomes of zebrafish and human share approximately 70% homology, which
has made zebrafish a desirable model for studying human diseases [30]. Segner reviewed
the studies which employed the zebrafish model to evaluate endocrine disrupting effects
of different EDCs, such as Bisphenol A (BPA), ethynylestradiol (EE2) and phytosterols [31].
Besides, researchers adopted zebrafish embryos for studying developmental toxic effects
of EDC exposures [32–34].
In the present review, a literature search was performed through Google Scholar (https:
//scholar.google.com/, accessed on 26 January 2021 (DEHP) and 17 March 2021 (MEHP))
with the keywords “DEHP AND zebrafish embryo” and “DEHP AND zebrafish larvae”
for DEHP exposures as well as the keywords “MEHP AND zebrafish embryo” and “MEHP
AND zebrafish larvae” for MEHP exposures. In particular, this review only included effects
of DEHP or MEHP exposures on zebrafish, which started from the embryonic stage. In
other words, studies that started to treat zebrafish with DEHP or MEHP at later devel-
opmental stages (i.e., larval, juvenile and adult stages) were excluded. Moreover, in the
present review, the term “acute exposure” referred to exposures which started from the
embryo stage to 1 week, while the term “chronic exposure” referred to exposures which
started from the embryo stage and assessment of the zebrafish at an age more than 1 week.
We summarized the effects of acute and chronic DEHP exposures on zebrafish, which
started from the embryonic stage, and analyzed acute and potential long-term effects in-
duced by acute exposures, and effects induced by chronic exposures of DEHP through
various biological endpoints at different developmental stages of the zebrafish, in order to
facilitate risk assessment on DEHP, as outlined in Figure 3.
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2. Acute Effects Induced by Acute Exposure
2.1. Lethal Effects
Standardized endpoints have been established for evaluating the mortality of zebrafish
embryos in toxicity tests. Lethal endpoints included coagulation of eggs or embryos, non-
detachment of tail, somite development failure as well as lack of heartbeat [36]. Increased
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mortality rate was reported in DEHP-exposed zebrafish embryos [37–39]. In particular,
Muhammad et al. found a mortality rate of 37.6% for zebrafish embryos at 72 h post-
fertilization (hpf) upon exposures to 0.5 µg/L DEHP [39]. Two separate studies made use
of the mortality rate at 168 hpf as the endpoint in order to compare the toxic effects on
zebrafish embryos among 6 types of phthalates, including DEP, DBP, DMP, BBzP, DnOP and
DEHP [37,38]. When exposed to 50 µg/L phthalate, the highest mortality rate (19.5%) was
found in DEHP-treated embryos among all phthalate-treated embryos [38]. However, when
a higher phthalate concentration (10 mg/L) was used, the mortality rate of DEHP ranked
5th among those tested phthalates [37]. The lethal concentration that caused 50% mortality
(LC50) of DEHP on zebrafish embryos was determined to be 2.5 µg/L in zebrafish embryos
at 72 hpf [40]. An independent study reported the LC50 value of DEHP for zebrafish
embryos from 72 to 168 hpf as 54.02 mg/L [41]. Regarding MEHP exposures, a significant
increase in the mortality rate was observed in MEHP-exposed embryos in a dose- and
time-dependent manner [42]. Table 1 summarizes the lethal effects from acute exposures to
DEHP or MEHP on zebrafish embryos.
Table 1. Lethal effects from acute exposures to (a) DEHP and (b) MEHP on zebrafish embryos. ** The concentration was
converted from nM or µM using the molar mass of MEHP 278.34 g/mol.
(a) DEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
mortality rate increased 0.5 µg/L 27–72 hpf 72 hpf [39]
25 µg/L 3–168 hpf 168 hpf [38]
200 mg/L 1–168 hpf 168 hpf [37]
survival (LC50) 2.5 µg/L start at embryo stage—72 hpf 72 hpf [40]
54.02 mg/L 72–168 hpf 72–168 hpf [41]
(b) MEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
mortality rate increased ** 2.8 mg/L start at embryostage—36/48/60/72/96 hpf
** 2.8 mg/L: 60, 72, 96 hpf;
** 7.0 mg/L & ** 14 mg/L:
36, 48, 60, 72, 96 hpf
[42]
2.2. Sublethal Effects
2.2.1. Developmental and Morphological Defects
To assess sublethal effects of a toxic substance, development toxicity and teratogenic
toxicity in zebrafish embryos were employed. Common morphological abnormalities
included altered hatching rate, altered body size, body weight and heart rate, body cur-
vature, induction of yolk sac and pericardial edema, spontaneous movement inhibition,
malformation in swim bladder as well as pigmentation [35,43].
An increased deformity rate was reported in DEHP-exposed zebrafish embryos [37,38,41].
The deformity rate reached 20% in zebrafish embryos treated with 10 mg/L DEHP, where
swimming-bladder inflation was the most commonly observed defect [41]. Pu et al. and
Hamid et al. coincidently reported bent spine as one of the discernable phenotypes [37,38].
DEHP treatment with 2.5 µg/L significantly reduced the hatching rate of zebrafish em-
bryos at 48 and 72 hpf compared to the control [44]. In a separate study, a hatching rate
62.4% was reported in the DEHP-treated group at 72 hpf, with the concentration as low as
0.5 µg/L [39]. On the other hand, body length reduction was reported in DEHP-exposed
zebrafish embryos [44–47]. Tran et al. reported that the body lengths of 120 hpf zebrafish em-
bryos were decreased upon DEHP exposures to the highest tested concentration (100 mg/L),
which were however not significantly different after DEHP exposures to lower concentrations
(0.5 µg/L–10 mg/L) [46]. Kinch et al. demonstrated that DEHP exposures induced a more se-
rious effect on the morphology at earlier time points (3–24 hpf and 3–48 hpf) than at later time
points (3–72 hpf) [45]. Exposures from 3 to 24 hpf to 5.2 nM DEHP significantly reduced the
body length, tail length as well as yolk extension length of zebrafish embryos compared to the
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control, while no effects were observed with DEHP exposures at 3–48 hpf and 3–72 hpf [45].
Opposite results were obtained by Ustundag et al. and Mu et al. in that DEHP could cause
yolk sac edema with longer treatment durations [44,48]. Mu et al. found that 250 µg/L of
DEHP significantly induced yolk sac edema in 48 hpf embryos as well as increased ratios
of yolk sac area to fish body area in DEHP-dosed embryos when compared with control
embryos [48]. In a separate study, Mu et al. reported that exposure to as low as 2.5 µg/L
of DEHP could cause yolk sac edema in 72 hpf embryos [44]. Kinch et al. found that the
forebrain lengths of embryos treated with DEHP from 3 to 48 hpf were significantly reduced
by 10% when compared to the negative controls [45]. In the same study, upon exposure to
DEHP or thyroid hormone, the head length was decreased by 20% relative to the controls
when exposed from 3 to 24 hpf. The results suggested that the head morphology might be
changed through interactions with thyroid hormone receptors [45]. Hyperemia and dark pig-
mentation were also detected in DEHP-exposed zebrafish embryos [41]. For MEHP exposures,
Park et at. reported effective concentrations (EC) based on biological responses (mortality
and abnormality) of zebrafish embryos after exposures to eight different concentrations of
MEHP (namely, 0, 0.1, 1.6, 3.1, 6.3, 12.5, 25 and 50 µg/mL) for 6 days [49]. No observed effect
concentration (NOEC), EC10, EC50 and EC100 were determined as <6.09, 9.77, 29.98 and
50 µg/mL, respectively [49]. Kamstra et al. reported reduction in body length [50], while
Sant et al. found abnormalities in the swim bladder in MEHP-exposed larvae [51]. On the
other hand, Lu et al. revealed decreases in the hatching rate, heart rate and body length as
well as increased deformity in MEHP-exposed embryos when compared to the controls [42].
Table 2 summarizes developmental and morphological defects from acute exposures to DEHP
or MEHP in zebrafish embryos.
Table 2. Developmental and morphological defects from acute exposures to (a) DEHP and (b) MEHP in zebrafish embryos.
* The concentration was converted from nM or µM using the molar mass of DEHP 390.57 g/mol. ** The concentration was
converted from nM or µM using the molar mass of MEHP 278.34 g/mol.
(a) DEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
hatching delayed 0.5 µg/L 27–72 hpf 72 hpf [39]
2.5 µg/L 4–48/72 hpf 48, 72 hpf [44]
deformity rate increased 25 µg/L 3–168 hpf 168 hpf [38]
200 mg/L 1–168 hpf 168 hpf [37]
body length decreased * 2.0 µg/L 3–24 hpf 24 hpf [45]
100 mg/L 2–120 hpf 120 hpf [46]
100 mg/L 6–168 hpf 168 hpf [47]
tail length decreased * 2.0 µg/L 3–24 hpf 24 hpf [45]
swim bladder inflation inhibited 500 µg/L 72–168 hpf 168 hpf [41]
yolk sac edema 2.5 µg/L 4–72 hpf 72 hpf [44]
50 µg/L 2–48 hpf 48 hpf [48]
yolk extension length decreased * 2.0 µg/L 3–24 hpf 24 hpf [45]
hyperemia 10 mg/L 72–168 hpf 168 hpf [41]
dark pigmentation 10 mg/L 72–168 hpf 168 hpf [41]
forebrain length decreased * 2.0 µg/L 3–48 hpf 48 hpf [45]
head width decreased * 2.0 µg/L 3–24 hpf 24 hpf [45]
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Table 2. Cont.
(b) MEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
hatching delayed ** 2.8 mg/L 4–76 hpf 76 hpf [42]
deformity rate increased ** 14 mg/L 4–76 hpf 76 hpf [42]
body length decreased ** 7.0 mg/L 4–76 hpf 76 hpf [42]
body length decreased ** 8.4 mg/L start at embryostage—3/6 dpf 3/6 dpf [50]
swim bladder abnormality 200 µg/L 6–96 hpf 96 hpf [51]
no observed effect
concentration (NOEC) <6.09 mg/L 6–144 hpf 144 hpf [49]
effective concentration, 10% (EC10) 9.77 mg/L 6–144 hpf 144 hpf [49]
effective concentration, 50% (EC50) 29.98 mg/L 6–144 hpf 144 hpf [49]
effective concentration, 100% (EC100) 50.0 mg/L 6–144 hpf 144 hpf [49]
2.2.2. Cardiovascular Toxicity
Studies report that DEHP could impose cardiovascular toxicity to zebrafish embryos.
Treatment with 250 µg/L DEHP induced intense apoptotic signals in the heart region
in zebrafish embryos at 72 hpf relative to the control [52]. On the other hand, DEHP
was reported to induce pericardial edema in zebrafish embryos [41,44,52]. Pericardial
edema was observed at 72 or 96 hpf after treatment with DEHP in the µg/L range [44,52].
Exposure to a higher DEHP concentration (10 mg/L) from 72 to 168 hpf also led to the
same effect [41]. However, effects on the heart rate induced by DEHP were different when
lower (in the µg/L range) or higher (in the mg/L range) doses were used. The heart rate in
zebrafish embryos has been widely used as an endpoint for assessing heart toxicity. Pu et al.
and Lu et al. demonstrated that DEHP doses in the mg/L range could reduce the heart
rate in embryos at 3 days post-fertilization (dpf) [37,42]. In contrast, the heart rate was
significantly increased in embryos at a later development stage (168 hpf) upon treatment
with lower DEHP doses (25 and 50 µg/L) [38]. For MEHP exposure, Lu et al. reported
reduction of heart rate in embryos upon treatment with MEHP in the mg/L range [42].
Table 3 summarizes the cardiovascular toxicity from acute exposures to DEHP or MEHP
on zebrafish embryos.
Table 3. Cardiovascular toxicity from acute exposures to (a) DEHP and (b) MEHP on zebrafish. * The concentration was
converted from nM or µM using the molar mass of DEHP 390.57 g/mol. ** The concentration was converted from nM or
µM using the molar mass of MEHP 278.34 g/mol.
(a) DEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
heart rate decreased * 20 mg/L 4–76 hpf 76 hpf [42]
120 mg/L 1–72 hpf 72 hpf [37]
heart rate increased 25, 50 µg/L 3–168 hpf 168 hpf [38]
pericardial edema 2.5 µg/L 4–72 hpf 72 hpf [44]
250 µg/L 1.5–72/96 hpf 72, 96 hpf [52]
10 mg/L 72–168 hpf 168 hpf [42]
apoptosis signal increased in heart region 250 µg/L 1.5–72 hpf 72 hpf [52]
(b) MEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
heart rate decreased ** 14 mg/L 4–76 hpf 76 hpf [42]
2.2.3. Skeletal Toxicity
DEHP has been associated with skeletal and spinal abnormalities [37,44]. Exposures
to DEHP from 4 to 72 hpf could instigate axial curvature in zebrafish embryos [44]. Bent
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spinal curvature as well as spinal dysplasia were also shown in DEHP-exposed zebrafish
embryos at 168 hpf [37]. Table 4 summarizes skeletal toxicity from acute exposure to DEHP
on zebrafish embryos.
Table 4. Skeletal toxicity from acute exposure to DEHP on zebrafish embryos.
Endpoint Lowest Effective Dose Exposure Endpoint Time References
bent spinal curvature 2.5 µg/L 4–72 hpf 72 hpf [44]
200 mg/L 1–168 hpf 168 hpf [37]
spinal dysplasia (cartilage effect) 200 mg/L 1–168 hpf 168 hpf [37]
2.2.4. Behavioral Toxicity
Exposures to DEHP have exerted behavioral toxicities on zebrafish embryos [37,42,46,53].
Spontaneous movement inhibition has been reported in zebrafish embryos upon DEHP
exposures [37,53]. Spontaneous movement was established as an important marker to assess
the developmental status and behavioral ability of zebrafish embryos, which was initiated by
the spinal cord at approximately 24 hpf and was suggested to associate with hatching [43]. In
one of the related studies, zebrafish embryos were exposed to seven concentrations of DEHP
(0, 10, 50, 90, 120, 150, 200 mg/L), and the automatic movement number in 20 s of the embryos
was assessed using a stereomicroscope at 24 hpf. The results showed that DEHP significantly
inhibited movement at higher concentrations (90–200 mg/L) [37]. Similar results were found
by Qian et al. who reported an inhibitory effect on the movement of zebrafish embryos upon
DEHP exposures as low as 50 µg/L [53]. Locomotor activity was another marker to assess the
behavioral ability in zebrafish embryos. DEHP exposure was confirmed to alter locomotor
activities in zebrafish embryos [42,46]. In a related study, zebrafish embryos were exposed to
four concentrations of DEHP (0, 10, 25, 50 µM) at 4 hpf, and after the 96 h exposure time point,
the swimming activities were recorded using the Zebralab Video-Track system (ViewPoint
Life Science, France) [42]. The results indicated that an exposure to 50 µM DEHP could
significantly inhibit the locomotor activity compared to the control [42]. In a separate study,
the locomotor activities under alternating light–dark conditions of DEHP-treated zebrafish
embryos at 120 hpf were evaluated via the ZebraBox tracking system (ViewPoint Life Science,
France) [46]. Suppression of locomotor activities was reported in DEHP-exposed embryos
under the dark condition, while stimulation of locomotor activities was found under the light
condition [46]. Together, the lowest effective concentration of DEHP in inhibition of locomotor
activity of zebrafish embryos was 5 µg/L as reported by Tran et al. [46]. As mentioned in
Section 2.2.1, morphological developmental effects were induced upon DEHP exposures to
as low as 2.0 µg/L (5.2 nM), with the observable body length, tail length, yolk sac extension
length, forebrain length and head width decreased as reported by Kinch et al. [45]. From
available data, the dose of DEHP, which triggered morphological effects, was lower than
that which inhibited locomotor activity in zebrafish embryos. No existing data showed
effect concentrations in locomotor activity at exposure levels where no morphological or
developmental abnormalities were observed. More studies are required for understanding the
relationship between morphological and developmental aberrations and behavioral toxicity
in zebrafish embryos. Table 5 summarizes the behavioral toxicity from acute exposures to
DEHP or MEHP on zebrafish embryos.
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Table 5. Behavioral toxicity from acute exposures to (a) DEHP and (b) MEHP on zebrafish embryos. * The concentration
was converted from nM or µM using the molar mass of DEHP 390.57 g/mol. ** The concentration was converted from nM
or µM using the molar mass of MEHP 278.34 g/mol.
(a) DEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
spontaneous movement decreased (no. of
spontaneous movements in 20 s) 50 µg/L 2–24 hpf 24 hpf [53]
movement inhibition 90 mg/L 1–24 hpf 24 hpf [37]
locomotor activity inhibited * 20 mg/L 4–100 hpf 100 hpf [42]
locomotor activity (dark) (bursting) decreased 5 µg/L 2–120 hpf 120 hpf [46]
locomotor activity (dark) (cruising) decreased 5 µg/L 2–120 hpf 120 hpf [46]
locomotor activity (light) (swimming) increased 10 mg/L 2–120 hpf 120 hpf [46]
locomotor activity (light) (cruising) increased 10 mg/L 2–120 hpf 120 hpf [46]
locomotor activity (light) (freezeing) increased 1 mg/L 2–120 hpf 120 hpf [46]
(b) MEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
locomotor activity inhibited ** 14 mg/L 4–100 hpf 100 hpf [42]
2.3. Regulation of Genes and Possible Mechanisms
In Section 2.2, we summarized the sublethal effects induced by DEHP or MEHP in
terms of developmental and morphological defects, cardiovascular, skeletal and behavioral
effects. The mechanisms behind DEHP- or MEHP-induced effects on zebrafish embryos
are important for understnading the mode of action. DEHP was reported to change gene
expression in zebrafish embryos, which was revealed using different techniques, including
immunohistochemical staining and reverse transcription polymerase chain reaction (RT-
PCR) analyses. Ustundag et al. studied the effect on gene expression upon the exposure of
2.5 µg/L of DEHP to zebrafish embryos from 4 to 48 hpf. Immunohistochemical staining
was applied to examine the expressions PCNA, Wnt3a and β-catenin genes in zebrafish
embryos [44]. Intense staining of PCNA, Wnt3a and β-catenin were observed in the DEHP
group compared to the weak staining shown in the control group. The authors further
conducted reverse transcription polymerase chain reaction (RT-PCR) analysis to examine
gene expressions in 72 hpf zebrafish embryos. Expression of gsk3β was significantly
increased in the DEHP group relative to the control [44]. Studies also reported that DEHP
altered gene expressions related to the skeletal development pathway in 96 hpf zebrafish
embryos [37,53]. Exposure of environmentally relevant concentrations of DEHP at 50 µg/L
significantly upregulated the expressions of genes in 96 hpf zebrafish embryos involved
in skeletal development in terms of skeleton (spp1), notochord (ngs, col8a1a) and muscle
(klhl41a, smyd2b, stac3) [53]. However, the expression of col8a1a was significantly reduced by
DEHP at 250 µg/L. Together, the results demonstrated that DEHP could lead to abnormal
development of the spine and skeletal system and the authors proposed that different
transcriptional effects could be induced under different concentrations [53]. Pu et al. also
reported that a higher concentration (200 mg/L) of DEHP activated the expression levels
of four major skeletal-related genes (sp7, runx2b, gpc4a, shha) in zebrafish embryos [37].
On the other hand, multi-omics approaches were also employed to investigate the
mechanisms of DEHP-induced developmental toxicities [48,52]. Omics approaches in
biology, including genomics, epigenomics, transcriptomics, proteomics, lipidomics and
metabolomics, can reveal alterations in different domains upon toxicant exposures and
provide insights into possible mechanisms as well as potential toxic effects and diseases [54].
Mu et al. examined the effects on zebrafish embryos upon exposures to 50 µg/L of DEHP
through transcriptomic, proteomic and lipidomic approaches [48]. From transcriptomic
profiling analysis, significant alteration was observed in expression of transcripts related to
different biological processes involved in lipid metabolism and skeletal development, e.g.,
steroid binding, lipid binding, lipid transport, fatty-acid metabolism, skeletal muscle tissue
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development, stress response as well as chemokine activity [48]. On the other hand, the data
from proteomic profiling analysis suggest significant changes in the levels of 235 proteins
(217 up-regulated and 18 down-regulated) [48]. The data revealed that DEHP significantly
induced various processes in zebrafish embryos, including lipase activity regulation, lipid
absorption, lipid catabolism and lipid metabolism [48]. REVIGO similarity analysis was
further applied, which revealed that lipid digestion, lipid metabolism, lipid transport and
lipase activity regulation were the major pathways activated by DEHP exposures [48].
From lipidomic profiling analysis, among 207 identified lipid species in zebrafish embryos,
DEHP was shown to significantly lower the levels of neutral glycosphingolipids (Creg1),
cholesterol esters (Che), diglycerides (DG), triglycerides (TG) and fatty acids (FA) [48].
The study also reported that DEHP altered the expression of protein levels involved in
immune responses (TNFα, NF-kβ, il-1β, il-8, tp63) [48]. Based on these findings, the
authors inferred that DEHP-induced immune response might be a result of disruption
of lipid homeostasis [48]. In a separate study, Mu et al. further investigated possible
developmental pathways upon exposures to 50 µg/L of DEHP via transcriptomic and DNA
methylation profile analysis, particularly the genes involved in heart development [52].
From transcriptomic analyses, among 32,477 genes in the reference genome of zebrafish,
the research group reported that 371 transcripts (234 up-regulated and 137 down-regulated)
were significantly altered in embryos after their exposure to 50 µg/L DEHP, followed
by the gene ontology analysis. [52]. The results showed that exposure to 50 µg/L of
DEHP significantly induced pathways of steroid binding (paqr5b, nr1h4, fabp10a), cyclase
activator activity (guca1a, guca1d), actomyosin structure organization (klhl41a, csrp3, cnn1b,
ctnt), chemokine receptor binding (ccl27a, ccl39.3), myofibril assembly (csrp3, klhl41a, ctnt),
notochord development (col8ala, ngs, fbn2b), skeletal system development (spp1), heart
contraction (smyd2b, csrp3) as well as heart process (smyd2b, csrp3), which were related
to heart development [52]. Differential gene transcriptions, including nppa, My17, Tbx5b,
smyd2b, klhl41a, ctnt and cmlc1 were altered in embryos after DEHP exposures, which
were further confirmed using quantitative polymerase chain reaction (qPCR) [52]. In the
same study, the global change of DNA methylation in zebrafish embryos was assessed
using methylated DNA immunoprecipitation sequencing (MeDIP-Seq). Mu et al. also
reported significant hypomethylation of nppa, ctnt and hypermethylation of tbx5b in DEHP-
exposed zebrafish embryos, which were related to heart development [52]. Comparisons
on transcriptomic and DNA methylation profiles suggested that transcriptional alteration
of gene might be associated with modified DNA methylation [52].
Junaid et al. studied the toxicity in zebrafish embryos induced by acute exposures to
DEHP at environmentally relevant concentrations (0–400 µg/L) [55]. The results showed
that 400 µg/L of DEHP could activate the PI3K-AKT-mTOR pathway in zebrafish embryos
as evidenced by significant upregulation of the transcripts of key genes involved in the
pathway (pik3r1, akt1, mtor, ps6kb) [55]. Junaid et al. further used the cyp1a transgenic
zebrafish to monitor the effect of DEHP exposure on the AhR activity. Concentration-
dependent increases in the levels of fluorescent signals in DEHP-exposed Tg(cyp1a:gfp)
zebrafish embryos were observed, which indicated that short-term low-concentration
exposures to DEHP could induce AhR activity in the embryos [55]. Do et al. also employed
transgenic zebrafish as the model particularly to explore possible mechanisms of DEHP-
induced abnormal neurobehavior. After confirming the inhibition of locomotor activities in
DEHP-exposed zebrafish embryos, as described in Section 2.2.4., the authors further found
significant reduction in fluorescent intensity in the transgenic zebrafish Tg (HuC:eGFP)
upon DEHP exposures [46]. The study further reported the potential of DEHP in interfering
with neurotransmission as evidenced through upregulation of ache and down regulation of
th gene expression, which were involved in the dopamine system [46].
Regarding MEHP exposures, Sant et al. observed that exposures to 200 µg/L of
MEHP significantly enhanced vacuolization and types of vacuolization in the livers of
96 hpf zebrafish larvae through histological analysis [51]. Furthermore, the zebrafish larvae
were exposed to 200 µg/L of MEHP from 6 to 120 hpf and were assessed on the 15th day
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through different endpoints. The lipid contents in the zebrafish larvae were assessed via red
O staining, which revealed that MEHP exposures significantly increased lipid accumulation
in the livers and brains in the larvae compared to the control group [51]. Expression of
peroxisome proliferator-activated receptor (PPAR) alpha target fabp1a1 was also found to
have increased in MEHP-exposed larvae [51]. A parallel experiment was also conducted to
investigate the involvement of nuclear factor erythroid 2-related factor 2 (Nrf2) signaling
in MEHP-induced larval steatosis using the nrf2a mutant zebrafish. However, the results
demonstrated that MEHP-induced larval steatosis was independent of Nrf2 signaling [51].
Table 6 summarizes the regulation of genes and possible mechanisms from acute exposures
to DEHP or MEHP on zebrafish embryos.
Table 6. Regulation of gene and possible mechanisms from acute exposures to (a) DEHP and (b) MEHP on zebrafish embryos.
(a) DEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
intense PCNA staining 2.5 µg/L 4–48 hpf 48 hpf [44]
intense wnt3a staining 2.5 µg/L 4–48 hpf 48 hpf [45]
intense β-catenin staining 2.5 µg/L 4–48 hpf 48 hpf [46]
gsk3β mRNA expression increased 2.5 µg/L 4–72 hpf 72 hpf [44]
bmp2 transcript level decreased 50 µg/L 2–96 hpf 96 hpf [53]
ngs transcript level increased 50 µg/L 2–96 hpf 96 hpf [53]
co18ala transcript level increased 50 µg/L 2–96 hpf 96 hpf [53]
co18ala transcript level decreased 250 µg/L 2–96 hpf 96 hpf [53]
klh14a transcript level increased 50 µg/L 2–96 hpf 96 hpf [53]
smyd2b transcript level increased 50 µg/L 2–96 hpf 96 hpf [53]
spp1 transcript level increased 50 µg/L 2–96 hpf 96 hpf [53]
stac3 transcript level increased 50 µg/L 2–96 hpf 96 hpf [53]
steroid binding pathway induction (paqr5b,
nr1h4, fabp10a) 50 µg/L 1.5–96 hpf 96 hpf [52]
cyclase activator activity pathway induction
(guca1a, guca1d) 50 µg/L 1.5–96 hpf 96 hpf [52]
actomyosin structure organization pathway
induction (klhl41a, csrp3, cnn1b, ctnt) 50 µg/L 1.5–96 hpf 96 hpf [52]
chemokine receptor binding pathway
induction(ccl27a, ccl39.3) 50 µg/L 1.5–96 hpf 96 hpf [52]
myofibril assembly pathway induction (csrp3,
klhl41a, ctnt) 50 µg/L 1.5–96 hpf 96 hpf [52]
notochord development pathway induction
(col8a1a, ngs, fbn2b) 50 µg/L 1.5–96 hpf 96 hpf [52]
skeletal system development pathway
induction (spp1) 50 µg/L 1.5–96 hpf 96 hpf [52]
heart contraction and heart process pathway
induction (smyd2b,csrp3) 50 µg/L 1.5–96 hpf 96 hpf [52]
nppa transcript level altered 50 µg/L 1.5–96 hpf 96 hpf [52]
My17 transcript level altered 50 µg/L 1.5–96 hpf 96 hpf [52]
Tbx5b transcript level altered 50 µg/L 1.5–96 hpf 96 hpf [52]
smyd2b transcript level altered 50 µg/L 1.5–96 hpf 96 hpf [52]
ctnt transcript level altered 50 µg/L 1.5–96 hpf 96 hpf [52]
cmlc1 transcript level altered 50 µg/L 1.5–96 hpf 96 hpf [52]
hypomethylation (nppa, ctnt) 50 µg/L 1.5–96 hpf 96 hpf [52]
hypermethylation (tbx5b) 50 µg/L 1.5–96 hpf 96 hpf [52]
immune system-related genes (cci27a, tnfaip2b,
casp3b, rnasel3, traf3ip2b, diexf, trpm2, park2,
smyd2b, creb312, il-1b, nfkb1, tp63, caspa) altered
50 µg/L 2–96 hpf 96 hpf [48]
Toxics 2021, 9, 193 11 of 23
Table 6. Cont.
(a) DEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
lipid metabolism and skeletal development
related genes (paqr5b, nr1h4, gc, fabp10a, esyt3,
zfos-411a11.2, alox5a, apoba, atp8b1, osbp19,
ch25hl1.2, gfpt1, klhl41a, klhl40b, stac3, ucmab,
spp1, caspa, hapln1b) altered
50 µg/L 2–96 hpf 96 hpf [48]
sp7 transcript level increased 200 mg/L 1–168 hpf 168 hpf [37]
runx2b transcript level increased 200 mg/L 1–168 hpf 168 hpf [38]
gpc4a transcript level increased 200 mg/L 1–168 hpf 168 hpf [39]
shha transcript level increased 200 mg/L 1–168 hpf 168 hpf [40]
elav13 expression decreased, Fluorescence
intensity reduction inTg (HuC:eGFP) 500 µg/L 2–72 hpf 72 hpf [46]
ache transcript level increased 50 µg/L 2–120 hpf 120 hpf [46]
th transcript level decreased 500 µg/L 2–120 hpf 121 hpf [46]
pik3r1 mRNA expression increased 400 µg/L 2–168 hpf 168 hpf [55]
akt1 mRNA expression increased 400 µg/L 2–168 hpf 168 hpf [55]
mtor mRNA expression increased 400 µg/L 2–168 hpf 168 hpf [55]
ps6kb mRNA expression increased 200 µg/L 2–168 hpf 168 hpf [55]
AhR activity induction, Fluorescence intensity
increased in Tg(cyp1a:gfp) 33 µg/L 2–120 hpf 120 hpf [55]
Cerg1 level decreased 50 µg/L 2–96 hpf 96 hpf [48]
Che level decreased 50 µg/L 2–96 hpf 96 hpf [48]
DG level decreased 50 µg/L 2–96 hpf 96 hpf [48]
TG level decreased 50 µg/L 2–96 hpf 96 hpf [48]
FA level decreased 50 µg/L 2–96 hpf 96 hpf [48]
lipase activity regulation, lipid absorption, lipid
catabolism, lipid digestion, lipid metabolism
and lipid transport increased
50 µg/L 2–96 hpf 96 hpf [48]
(b) MEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
increased vacuolization and type of
vacuolization in liver 200 µg/L 6–96 hpf 96 hpf [51]
lipid accumulation in liver & brain 200 µg/L 6–120 hpf 15 dpf [51]
fabp1a1 expression increased 200 µg/L 6–120 hpf 15 dpf [51]
3. Potential Long-Term Effects Induced by Acute Exposure
In addition to acute developmental and teratogenic toxicity in zebrafish embryos,
assessments through various biological endpoints also revealed long-term effects. Examples
of established biomarkers in the fish model included immune modulation, endocrine
disruption as well as genotoxicity [56]. In this section, we reviewed potential long-term
effects induced by DEHP exposure in zebrafish embryos in terms of oxidative stress,
apoptosis and genotoxicity, transgenic effect as well as endocrine disruption.
3.1. Induction of Oxidative Stress
It was well established that oxidant–antioxidant balance played a critical role in
organisms to maintain cellular development growth and survival. DEHP was found to
upset the oxidant–antioxidant balance in zebrafish embryos [38,40,42]. Lu et al. reported
the increased ROS generation and decreased superoxide dismutase (SOD) activity in
28 hpf embryos after DEHP and MEHP exposures [42]. In a separate study, enhanced
expression of oxidative stress-related genes (CAT, CuSOD, MnSOD) were reported in
zebrafish embryos upon exposures to 50 µg/L of DEHP [38]. Upset of oxidant–antioxidant
balance in embryos was also reported in DEHP-exposed zebrafish embryos in terms of
increased lipid peroxidation (LPO) and decreased glutathione-S-transferase (GST) levels
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exposed to as low as 2.5 µg/L of DEHP [40]. Table 7 summarizes the induction of oxidative
stress from acute exposures to DEHP or MEHP on zebrafish embryos.
Table 7. Induction of oxidative stress from acute exposures to (a) DEHP and (b) MEHP on zebrafish embryos. * The
concentration was converted from nM or µM using the molar mass of DEHP 390.57 g/mol. ** The concentration was
converted from nM or µM using the molar mass of MEHP 278.34 g/mol.
(a) DEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
lipid peroxidation (LPO) increased 2.5 µg/L start at embryo stage—72 hpf 72 hpf [40]
glutathione S-transferase (GST) decreased 2.5 µg/L start at embryo stage—72 hpf 72 hpf [40]
CAT expression increased 50 µg/L 3–96 hpf 96 hpf [38]
CuSOD expression increased 50 µg/L 3–96 hpf 96 hpf [39]
MnSOD expression increased 50 µg/L 3–96 hpf 96 hpf [40]
ROS generation increased * 20 mg/L 4–28 hpf 28 hpf [42]
SOD activity decreased * 20 mg/L 4–28 hpf 28 hpf [42]
(b) MEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
ROS generation increased ** 14 mg/L 4–28 hpf 28 hpf [42]
SOD activity decreased ** 14 mg/L 4–28 hpf 28 hpf [42]
3.2. Apoptosis and Genotoxicity
Genotoxic effects of DEHP were confirmed in various in vitro and in vivo studies and
was reviewed by Caldwell, including induction of DNA damages, abnormal regulation
of mitotic rate, apoptosis and cell prolifreation as well as activation of different nuclear
receptors, which could contribute to cancer progression [57]. DNA damages could be
induced by direct action of parental compounds of environmental contaminants or their
metabolites or through indirect action by the generated reactive oxygen species (ROS) [58].
Embryos were exposed to five sublethal concentrations of DEHP (namely, 0, 0.5, 1, 5 and
10 mg/L) from 72 to 168 hpf, and DNA damages in cells of the embryos were then analyzed
using comet assay [41]. The results demonstrated that DEHP significantly induced DNA
strand breaks in embryos in a concentration dependent manner, when compared to controls.
Boran et al. further reported upregulation of the tumor suppressor gene p53 as well as
DNA repair genes rad51 and xrcc5 in DEHP-exposed embryos [41]. Lu et al. further studied
the involvement of the BER pathway in DEHP- and MEHP-treated zebrafish embryos
through measuring the mRNA levels of genes related to the BER pathway [42]. The results
showed that DEHP exposures significantly increased mRNA levels of ogg1, parp1, pcna, fen1
and lig1, while MEHP exposures significantly increased mRNA levels of ogg1, nthl1, apex1,
aprp1, xrcc1, lig3, ung, pcna, fen1 and lig1, which suggested that the BER pathway played
critical roles in DEHP- and MEHP-induced oxidative stress through repairing oxidative
DNA damages [42].
Besides, DEHP was confirmed to induce apoptosis and alter apoptosis-related genes
(cas8, cas9, pf3, bcl, bax) in zebrafish embryos [38,42,52]. Acridine orange (AO) staining
was established as a widely used technique to study apoptosis in zebrafish embryos.
Various studies used AO staining to investigate DEHP-induced apoptosis in zebrafish
embryos [38,52]. Exposures to 250 µg/L of DEHP from 1.5 to 72 hpf induced apoptotic
signals in zebrafish embryos, and intense apoptotic signals were observed in the heart
region [52]. Hamid et al. also observed an elevated number of apoptotic cells in DEHP-
treated zebrafish embryos with a lower DEHP concentration (50 µg/L) and for a longer
exposure (3–96 hpf) [38]. In the same study, increased mRNA levels of the apoptosis-related
genes cas8, cas9, pf3 and bax were detected in DEHP-treated embryos [38]. In a separate
study, mRNA expressions of bcl2 and bax were found to increase in 28 hpf embryos upon
exposures to higher concentrations of DEHP (25–50 µM) [42]. The mRNA levels of bcl2
and bax in zebrafish embryos were also significantly altered after MEHP exposures [42].
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Ustundag et al. investigated the relationship between oxidant–antioxidant balance and
expression of c-myc, which was the gene that regulated cell proliferation and apoptosis.
Increased expression of c-myc in DEHP-exposed embryos was reported, which was thus
proposed as a protective mechanism to preserve oxidant–antioxidant balance in zebrafish
embryos [40]. Table 8 summarizes the induction of apoptosis and genotoxicity from acute
exposures to DEHP or MEHP in zebrafish embryos.
Table 8. Apoptosis and genotoxicity from acute exposures to (a) DEHP and (b) MEHP on zebrafish embryos. * The
concentration was converted from nM or µM using the molar mass of DEHP 390.57 g/mol. ** The concentration was
converted from nM or µM using the molar mass of MEHP 278.34 g/mol.
(a) DEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
apoptosis signal increased 50 µg/L 3–96 hpf 96 hpf [38]
apoptosis signal increased (heart region) 250µg/L 1.5–72 hpf 72 hpf [52]
bax mRNA expression decreased 50 µg/L 3–96 hpf 96 hpf [38]
bax mRNA expression increased * 20 mg/L 4–28 hpf 28 hpf [42]
bcl2 mRNA expression decreased * 9.8 mg/L 4–28 hpf 28 hpf [42]
ctnt transcription level increased 50 µg/L 1.5–96 hpf 96 hpf [52]
ctnt protein level increased 50 µg/L 1.5–96 hpf 96 hpf [52]
nppa transcription level increased 50 µg/L 1.5–96 hpf 96 hpf [52]
Nppa protein level increased 50 µg/L 1.5–96 hpf 96 hpf [52]
cas8 mRNA expression increased 50 µg/L 3–96 hpf 96 hpf [38]
cas9 mRNA expression increased 50 µg/L 3–96 hpf 96 hpf [38]
pf3 mRNA expression increased 50 µg/L 3–96 hpf 96 hpf [38]
ogg1 mRNA expression increased * 20 mg/L 4–28 hpf 28 hpf [42]
parp1 mRNA expression increased * 3.9 mg/L 4–28 hpf 28 hpf [42]
pcna mRNA expression increased * 3.9 mg/L 4–28 hpf 28 hpf [42]
polb mRNA expression increased * 3.9 mg/L 4–28 hpf 28 hpf [42]
pold mRNA expression decreased * 3.9 mg/L 4–28 hpf 28 hpf [42]
fen1 mRNA expression increased * 20 mg/L 4–28 hpf 28 hpf [42]
lig1 mRNA expression increased * 3.9 mg/L 4–28 hpf 28 hpf [42]
c-myc transcript level increased 2.5 µg/L start at embryo stage—72 hpf 72 hpf [40]
DNA breaks increased 5 mg/L 72–168 hpf 168 hpf [41]
p53 mRNA expression increased 500 µg/L 72–168 hpf 168 hpf [41]
rad51 expression increased 1 mg/L 72–168 hpf 168 hpf [41]
xrcc5 expression increased 1 mg/L 72–168 hpf 168 hpf [41]
(b) MEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
bax mRNA level increased ** 2.8 mg/L 4–28 hpf 28 hpf [42]
bcl2 mRNA level decreased ** 14 mg/L 4–28 hpf 28 hpf [42]
ogg1 mRNA expression increased ** 2.8 mg/L 4–28 hpf 28 hpf [42]
nthl1 mRNA expression increased ** 2.8 mg/L 4–28 hpf 28 hpf [42]
apex1 mRNA expression increased ** 7.0 mg/L 4–28 hpf 28 hpf [42]
parp1 mRNA expression increased ** 2.8 mg/L 4–28 hpf 28 hpf [42]
xrcc1 mRNA expression increased ** 7.0 mg/L 4–28 hpf 28 hpf [42]
lig3 mRNA expression increased ** 2.8 mg/L 4–28 hpf 28 hpf [42]
ung mRNA expression increased ** 2.8 mg/L 4–28 hpf 28 hpf [42]
pcna mRNA expression increased ** 2.8 mg/L 4–28 hpf 28 hpf [42]
polb mRNA expression decreased ** 7.0 mg/L 4–28 hpf 28 hpf [42]
pold mRNA expression decreased ** 2.8 mg/L 4–28 hpf 28 hpf [42]
fen1 mRNA expression increased ** 7.0 mg/L 4–28 hpf 28 hpf [42]
lig1 mRNA expression increased ** 14 mg/L 4–28 hpf 28 hpf [42]
3.3. Transgenerational Effect
Kamstra et al. investigated the transgenerational effect of MEHP exposures among
three generations of zebrafish larvae (denoted as F0, F1 and F2), with only the F0 generation
having been exposed to 30 µM of MEHP from 0 to 6 dpf [50]. Body length differences were
Toxics 2021, 9, 193 14 of 23
reported in F0 larvae at 3 and 6 dpf, which had been exposed to MEHP, while no effect was
reported in F1 and F2 larvae [50]. Altered dnmt gene expressions (dnmt1, dnmt3aa, dnmt3ab,
dnmt3bb.1, dnmt3bb.2) and decreased global hmC levels were reported in F0 larvae at 6 dpf.
Furthermore, global demethylation in livers of F0 adult female zebrafish and reduction
of global hmC levels in brain tissues of F0 adult male zebrafish were detected [50]. In the
same study, MEHP exposure was found to lead to a significant increase in the average
methylation at conserved non-genic elements in zebrafish (zfCNEs) when compared to
the control [50]. The pathways involved in adipogenesis were enriched after MEHP
exposures, which were suggested to link to a potential obesogenic effect of MHEP [50].
Transgenerational effects were further assessed through locus-specific methylation analysis
by comparing differences of the methylation pattern among the three generations (F0
at 6 dpf, F1 at 6 dpf, F2 at 6 dpf, F0 at 15 dpf and F0 adult sperm). Transgenerational
effects were shown at the cbfa2t2 locus and specific CpG sites [50]. Table 9 summarizes the
transgenerational effect from acute exposure to MEHP on zebrafish embryos.
Table 9. Transgenerational effect from acute exposure to MEHP on zebrafish embryos. ** The concentration was converted
from nM or µM using the molar mass of MEHP 278.34 g/mol.
Endpoint Lowest Effective Dose Exposure Endpoint Time References
dnmt gene expressions altered (dnmt1,
dnmt3aa, dnmt3ab,
dnmt3bb.1, dnmt3bb.2)
F0: ** 8.4 mg/L F0: start at embryostage—6 dpf F0 6 dpf [50]
global demethylation in liver F0: ** 8.4 mg/L F0: start at embryostage—6 dpf F0 adult female [50]
global hmC level decreased F0: ** 8.4 mg/L F0: start at embryostage—6 dpf F0 6 dpf [50]
global hmC level decreased in
brain tissue F0: ** 8.4 mg/L
F0: start at embryo
stage—6 dpf F0 adult male [50]
average methylation increased
at zfCNEs F0: ** 8.4 mg/L
F0: start at embryo
stage—6 dpf F0 6 dpf [50]
adipogenesis pathway increased F0: ** 8.4 mg/L F0: start at embryostage—6 dpf F0 6 dpf [50]
transgenerational effect: DNA
methylation at cbfa2t2 locus and
specific CpG sites among F0, F1 and
F2 generations
F0: ** 8.4 mg/L F0: start at embryostage—6 dpf
F0 6 dpf, F1 6 dpf, F2




DEHP was reported to cause endocrine disruptions in zebrafish embryos [38,47,48,55,59,60].
Jia et al. demonstrated that DEHP exposures disrupted homeostasis of thyroid hormones (THs)
and altered expression of critical genes related to hypothalamus–pituitary–thyroid (HPT) axis in
the zebrafish [59]. In that study, zebrafish embryos were exposed to five concentrations of DEHP,
namely, 0, 40, 100, 200 and 400 µg/L from 2 to 168 hpf. The results revealed that whole-body
thyroxinem (T4) and triiodothyronine (T3) were significantly increased after exposure to the
highest tested concentration of DEHP, which subsequently led to disruption of homeostatic
balance of the thyroid hormone [59]. The authors further indicated that DEHP changed the ex-
pression of thyroid stimulating hormone (tshβ), corticotrophin releasing hormone (crh), uridine
diphosphate glucuronosyl transferase (ugt1ab), iodothyronine deiodinase (dio2), transthyretin
(ttr) and NK2 homeobox 1 (nkx2.1) involved in thyroid development and thyroglobulin (tg)
involved in thyroid synthesis [59]. Upregulation of tshβ and crh due to DEHP exposures were
also observed in a dose dependent manner [59].
In a separate study, 50 µg/L of DEHP exposure was found to have significantly altered
the expression of transcripts or proteins related to endocrine responses, including T3, T4,
17βestradiol and estrogen receptor alpha (ERα) [48]. Hamid et al. revealed that DEHP
could perturb the hypothalamic–pituitary–gonadal (HPG) axis in zebrafish embryos [38],
where the HPG axis was proved to be essential for normal function of the reproductive
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system in fish [61]. Significant upregulations of expressions in HPG-axis-pathway-related
genes including erα, estrogen receptor beta (erβ), androgen receptor (ar), cytochrome
P450 aromatase (cyp19a) and vitellogenin (vtg) in zebrafish embryos were observed upon
exposures to 50 µg/L of DEHP. The results showed that DEHP altered erα, erβ expressions
in a concentration dependent manner [38]. In a separate study, An et al. also reported
significant upregulation of erα and vtg expressions in embryos upon exposures to 0.1 mg/L
of DEHP; however, no significant differences were found in erβ expressions [60]. The
study also found increased expression of cyp19b in DEHP-exposed zebrafish embryos [60].
In relation, Lee et al. reported that the transcript level of HPG-axis-related genes (vtg1,
erα, cyp19a1b) were significantly altered upon DEHP exposures [47]. In another study,
Junaid et al. studied cancer cell migration in DEHP-exposed zebrafish through injection
of labelled breast cancer cells into 72 hpf larvae followed by two different levels of DEHP
exposures (400 and 1600 µg/L) for 6 h [55]. The distances traveled by cancer cells in
zebrafish were determined through the fluorescence sites and intensities. DEHP-induced
cancer-cell migration was confirmed through changes in the fluorescence distribution in
the yolk, gut and tail in two DEHP-dosed groups when compared to the control group,
while the total fluorescence intensity was unchanged [55].
MEHP was also found to cause endocrine disruptions in zebrafish embryos [62–65].
Zhai et al. reported MEHP exposures elevated T3 and reduced T4 contents in zebrafish
embryos [62]. The results linked the genes involved in thyroid hormone metabolism
(iodothyronine deiodinase (Dio2), UDP-glucuronosyltransferases (UGT1ab)) to T4 content
reduction. The genes related to thyroid development (Nkx2.1, Paired Box 8 (Pax8)), thyroid
hormone synthesis (TSHβ, sodium/iodide symporter (NIS) and TG) and TH transport
(transthyretin, TTR) were significantly altered after MEHP exposures [62]. In a separate
study, MEHP was reported to disrupt glutahione (GSH) homeostasis in zebrafish em-
bryos [63]. GSH played a critical role in embryonic development and organogenesis, which
were revealed through monochlorobimane (MCB) staining [63]. In this study, the zebrafish
were exposed to 200 µg/L MEHP from 3 hpf to either 48 or 72 hpf. Reductions in MCB
fluorescence intensities in the body, heart, brain ventricle and somite 12 were found at
both time points, while more serious disruptions were observed in 48 hpf embryos. These
results confirmed that MEHP exposures disrupted GSH utilization in specific tissues during
embryo development [63]. In separate studies, MEHP was found to disrupt pancreatic
organogenesis in zebrafish embryos [64,65]. The endocrine tissue within the pancreas was
called islet of Langerhans, which contained α-cells and β-cells responsible for secreting
glucagon and insulin, respectively. Sant et al. studied the effect of exposures to 0.7 µM
MEHP on the pancreatic islet development in transgenic zebrafish Tg(ins:GFP) embryos
at 48 hpf [65], and demonstrated that MEHP produced hypomorphic islets with evidence
of reduction in β-cell cluster area [65]. In relation, Jacob et al. confirmed that exposures
to 200 µg/L MEHP reduced β-cell as well as α-cell cluster area in transgenic zebrafish
Tg(ins:GFP) and Tg(gcga:GFP), respectively. Both these studies confirmed MEHP exposures
increased the frequency of pancreatic islet morphology variants such as fragmented and
ectopic islets, relative to the control [64,65]. Jacob et al. also reported that MEHP expo-
sures altered expression of genes related to endocrine hormone (preproinsulin a (insa),
somatostatin 2 (sst2)), exocrine (pancreasspecific transcription factor 1a, ptf1a) and glu-
tathione (GSH) (glutathione disulfide reductase (gsr), glutathione S-transferase pi 1 (gstp))
in wildtype zebrafish embryos. Changes in the pancreatic structure were also observed in
MEHP-exposed wildtype and mutant zebrafish embryos [64]. Table 10 summarizes the
endocrine disruption from acute exposures to DEHP or MEHP in zebrafish embryos.
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Table 10. Endocrine disruption from acute exposures to (a) DEHP and (b) MEHP in zebrafish embryos. ** The concentration
was converted from nM or µM using the molar mass of MEHP 278.34 g/mol.
(a) DEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
triiodothyronine (T3) level increased 400 µg/L 2–168 hpf 168 hpf [59]
triiodothyronine (T3) level increased 250 µg/L 2–96 hpf 96 hpf [48]
thyroxinem (T4) level increased 400 µg/L 2–168 hpf 168 hpf [59]
thyroxinem (T4) level increased 250 µg/L 2–96 hpf 96 hpf [48]
estrogen receptor alpha (erα)
mRNA increased 50 µg/L 3–96 hpf 96 hpf [38]
estrogen receptor alpha (erα)
mRNA increased 250 µg/L 2–96 hpf 96 hpf [48]
estrogen receptor alpha (ERα) gene
expression increased 100 µg/L
start at embryo
stage—168 hpf 168 hpf [60]
estrogen receptor alpha (ERα) protein
level increased 250 µg/L 2–96 hpf 96 hpf [48]
estrogen receptor alpha (erα) transcript
level decreased 10 µg/L 6–168 hpf 168 hpf [47]
estrogen receptor beta (erβ)
mRNA increased 50 µg/L 3–96 hpf 96 hpf [38]
cytochrome P450 aromatase (cyp19a)
expression increased 25 µg/L 3–96 hpf 96 hpf [38]
cytochrome P450 aromatase (Cyp19b) gene
expression increased 100 µg/L
start at embryo
stage—168 hpf 168 hpf [60]
cytochrome P450 aromatase (cyp19a1b)
transcript level increased 10 µg/L 6–168 hpf 168 hpf [47]
vitellogenin (vtg) mRNA
expression increased 25 µg/L 3–96 hpf 96 hpf [38]
vitellogenin (Vtg) gene
expression increased 100 µg/L
start at embryo
stage—168 hpf 168 hpf [60]
vitellogenin (vtg1) transcript
level increased 100 µg/L 6–168 hpf 168 hpf [47]
thyroid stimulating hormone (tshβ)
mRNA expression increased 100 µg/L 2–168 hpf 168 hpf [59]
corticotrophin releasing hormone (crh)
mRNA expression increased 200 µg/L 2–168 hpf 168 hpf [59]
NK2 homeobox 1 (nkx2.1) mRNA
expression increased 200 µg/L 2–168 hpf 168 hpf [59]
thyroglobulin (tg) mRNA




200 µg/L 2–168 hpf 168 hpf [59]
iodothyronine deiodinase (dio2) mRNA
expression increased 400 µg/L 2–168 hpf 168 hpf [59]
transthyretin (ttr) mRNA
expression increased 200 µg/L 2–168 hpf 168 hpf [59]
androgen receptor (ar) mRNA
expression increased 50 µg/L 3–96 hpf 96 hpf [38]
17βestradiol level increased 250 µg/L 2–96 hpf 96 hpf [48]
cancer cell migration (from yolk to gut
and tail) 400 µg/L 72–78 hpf 78 hpf [55]
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(b) MEHP
Endpoint Lowest Effective Dose Exposure Endpoint Time References
triiodothyronine (T3) level increased 200 µg/L 2–168 hpf 168 hpf [62]
thyroxinem (T4) level decreased 200 µg/L 2–168 hpf 168 hpf [62]
thyroid stimulating hormone (TSHβ)
transcription increased 40 µg/L 2–168 hpf 168 hpf [62]
NK2 Homeobox 1 (Nkx2.1)
transcription increased 8 µg/L 2–168 hpf 168 hpf [62]
thyroglobulin (TG) transcription increased 200 µg/L 2–168 hpf 168 hpf [62]
UDP-glucuronosyltransferases (UGT1ab)
transcription increased 40 µg/L 2–168 hpf 168 hpf [62]
iodothyronine deiodinase (Dio1)
transcription increased 8 µg/L 2–168 hpf 168 hpf [62]
iodothyronine deiodinase (Dio2)
transcription increased 40 µg/L 2–168 hpf 168 hpf [62]
transthyretin (TTR)
transcription decreased 200 µg/L 2–168 hpf 168 hpf [62]
paired box 8 (Pax8)
transcription increased 8 µg/L 2–168 hpf 168 hpf [62]
sodium/iodide symporter (NIS)
transcription increased 40 µg/L 2–168 hpf 168 hpf [62]
GSH disruption in body, heart, brain
ventricle and somite 12 (MCB
fluorescence decreased)
200 µg/L 3–48/72 hpf 48/72 hpf [63]
hypomorphic islets (β-cell cluster area
decreased)(Tg (ins:GFP)) ** 195 µg/L 3–48 hpf 48 hpf [65]
pancreatic islet variants and
defects decreased ** 195 µg/L 3–48 hpf 48 hpf [65]
hypomorphic islets (β-cell cluster area
decreased)(Tg (ins:GFP)) 200 µg/L 3–48/72/96/168 hpf 48/72/96/168 hpf [64]
hypomorphic islets (α-cell cluster area
decreased) (Tg (gcga:GFP)) 200 µg/L 3–48/72/96/168 hpf 48/72/96/168 hpf [64]
frequency of pancreatic islet morphology
variants increased 200 µg/L 3–48/72/96/168 hpf 48/72/96/168 hpf [64]
pancreatic structure altered in wt
zebrafish embryo 200 µg/L 3–48/72/96 hpf 48/72/96 hpf [64]
pancreatic structure altered in m
zebrafish embryo 200 µg/L 3–48/72/96 hpf 48/72/96 hpf [64]
preproinsulin a (insa)
expression decreased 200 µg/L 3–96 hpf 96 hpf [64]
somatostatin 2 (sst2) expression decreased 200 µg/L 3–96 hpf 96 hpf [64]
pancreasspecifictranscription factor 1a
(ptf1a) expression decreased 200 µg/L 3–96 hpf 96 hpf [64]
glutathione-disulfide reductase (gsr)
expression increased 200 µg/L 3–96 hpf 96 hpf [64]
glutathione S-transferase pi 1 (gstp)
expression decreased 200 µg/L 3–96 hpf 96 hpf [64]
4. Effects from Chronic Exposure
Chronic toxicities on the development, reproduction and intestines in zebrafish were
assessed after exposures to DEHP from the embryo to adult stage [39,66]. After being
exposed for 1 month to 0.5 µg/L DEHP, the mortality rate of hatchlings was reported as
60.57%, compared to the rate of 11.11% observed for the control group [39]. Muhammad
et al. assessed developmental and reproductive toxicities in zebrafish upon 6-month
exposures to 0.5 µg/L DEHP through the survived hatchlings at 1 month. Both the body
lengths and weights of female and male zebrafish adults were significantly reduced [39].
After 6-month DEHP exposures, the gonad somatic index (GSI) was reduced for both
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female and male zebrafish adults, which implied interruption of gonad development.
Breeding disruption in zebrafish adults was also reported in terms of decreasing egg
production and increasing non-fertilization rate [39]. Muhammad et al. further applied
histological examination to investigate the development of testis and ovary in zebrafish
treated with 0.5 µg/L of DEHP. The testes and ovaries of zebrafish in the control group were
confirmed normal. In the DEHP-dosed male group, well-developed testes were observed
while disruption of tubules as well as reduction in spermatogonia and spermatocyte
were found [39]. In the DEHP-dosed female group, undeveloped ovaries were identified
from the peri-nucleolar oocytes and early cortical alveolar oocytes [39]. These results
showed that long-term DEHP exposures posed toxicity on growth, reproduction and
fecundity in zebrafish. In a separate study, a gender-based zebrafish study was conducted
to investigate the effects of exposures to environmental concentrations (0, 10, 33, 100 µg/L)
of DEHP in embryos to 3.5-month adults [66]. Increased body lengths and weights as
well as altered intestinal microbiota and bacteria were reported in both male and female
zebrafish following DEHP exposures [66]. Increased conditional factors (K) were found
in female zebrafish treated with 10 µg/L of DEHP and in male zebrafish treated with
33 µg/L of DEHP. Reduction in villus width and goblet cells per villus in male and
reduction of tunica muscularis thickness in female were also reported in DEHP-treated
zebrafish via histological analysis [66]. Besides, in the intestines of DEHP-treated zebrafish,
the content of energy metabolites (TG, PY, FA, Glu) and the expression of key genes
involved in immune response (tlr-5, il-1β, nf-kb, il-8) were altered [66]. Based on these
results, the study suggested that DEHP could induce obesity as evidenced from altered
developmental indices, intestinal microbial community and metabolic homeostasis [66].
Table 11 summarizes the effects from chronic exposure to DEHP on zebrafish embryos.
Table 11. Effects from chronic exposure to DEHP on zebrafish embryos.
Endpoint Lowest Effective Dose Exposure Endpoint Time References
mortality rate increased 0.5 µg/L 27 hpf—1 month 1 month [39]
body length increased (male) 33 µg/L start at embryostage—3.5 month 3.5 month [66]
body length decreased (male) 0.5 µg/L 27 hpf—6 month 6 month [39]
body length increased (female) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
body length decreased (female) 0.5 µg/L 27 hpf—6 month 6 month [39]
body weight increased (male) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
body weight decreased (male) 0.5 µg/L 27 hpf—6 month 6 month [39]
body weight increased (female) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
body weight decreased (female) 0.5 µg/L 27 hpf—6 month 6 month [39]
intestinal microbiota alteration (female) 100 µg/L start at embryostage—3.5 month 3.5 month [66]
intestinal microbiota alteration (male) 100 µg/L start at embryostage—3.5 month 3.5 month [66]
intestinal bacteria alteration (female) 100 µg/L start at embryostage—3.5 month 3.5 month [66]
intestinal bacteria alteration (male) 100 µg/L start at embryostage—3.5 month 3.5 month [66]
villus width decreased (male) 100 µg/L start at embryostage—3.5 month 3.5 month [66]
tunica muscularis thickness
decreased (female) 100 µg/L
start at embryo
stage—3.5 month 3.5 month [66]
goblet cells per villus decreased (female) 100 µg/L start at embryostage—3.5 month 3.5 month [66]
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Endpoint Lowest Effective Dose Exposure Endpoint Time References
tlr-5 mRNA expression decreased (female) 100 µg/L start at embryostage—3.5 month 3.5 month [66]
il-1β mRNA expression decreased (female) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
il-8 mRNA expression increased (male) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
il-8 mRNA expression increased (female) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
TG content increased (male) 33 µg/L start at embryostage—3.5 month 3.5 month [66]
TG content increased (female) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
PY content increased (male) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
PY content increased (female) 33 µg/L start at embryostage—3.5 month 3.5 month [66]
FA content increased (male) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
Glu content increased (female) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
conditional factor increased (male) 33 µg/L start at embryostage—3.5 month 3.5 month [66]
conditional factor increased (female) 10 µg/L start at embryostage—3.5 month 3.5 month [66]
Gonad somatic index (GSI) decreased (male) 0.5 µg/L 27 hpf—6 month 6 month [39]
Gonad somatic index (GSI)
decreased (female) 0.5 µg/L 27 hpf—6 month 6 month [39]
egg production decreased 0.5 µg/L 27 hpf—6 month 6 month [39]
non-fertilization rate increased 0.5 µg/L 27 hpf—6 month 6 month [39]
spermatogonia and spermatocyte
decreased (male) 0.5 µg/L 27 hpf—6 month 6 month [39]
tubules distruption (male) 0.5 µg/L 27 hpf—6 month 6 month [39]
ovary development inhibition (female) 0.5 µg/L 27 hpf—6 month 6 month [39]
number of vitellogenic oocytes
decreased (female) 0.5 µg/L 27 hpf—6 month 6 month [39]
5. Summary
DEHP is the most extensively applied phthalate accounting for nearly 50% of global
phthalate consumption and has been associated with various adverse health effects. Health
concerns have been raised regarding DEHP exposures and in consequence, risk assessment
on DEHP exposures has become a required procedure. In the present review, we focused
on the toxicities induced by acute or chronic DEHP exposures on zebrafish embryos
with the exposure window, which started from the embryo stage. Apart from the parent
phthalate DEHP, its major metabolite MEHP could also be detected in the human body
and related to different adverse health effects, which was mentioned in Section 1. Both the
parent phthalate, DEHP, and its major metabolite, MEHP, could induce various adverse
developmental effects on zebrafish embryos upon acute or chronic exposures, which were
summarized in Tables 1–11, with the lowest effective dose, exposure widow and time point
for assessing each of the biological endpoints in order to facilitate the comparison between
the outcomes from different studies.
The linkage between various developmental and teratogenic toxicities and the under-
lying mechanisms requires further investigation. For comparing the toxicities of DEHP
and MEHP exposures, a parallel experiment showed that the lowest effective doses of
DEHP and MEHP were different to induce the reduction of survival rate, hatching rate and
body length as well as an increase in deformity rate [42]. Besides, the data from a zebrafish
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developmental screening showed that only the active metabolite MEHP was toxic, while
the parent DEHP tested negative in the concentration-response study [67]. More studies
are required to investigate the lowest effective dose as well as mechanisms underlying
different developmental effects of DEHP and MEHP, and to further reveal whether they
pose the same toxic effects through the same mechanisms to living organisms.
As many key developmental signaling pathways and their regulations are conserved
between zebrafish and mammals, the zebrafish model has been employed for investigating
mammalian disease as well as developmental pathways on the molecular basis [68,69].
MEHP have been shown to induce hepatic toxicity [51], and DEHP have been reported to al-
ter critical genes related to HPT axis and produce reproductive toxicity on zebrafish [39,58].
Since zebrafish develops relevant structures, e.g., liver for metabolic conversions [70]
as well as the thyroid gland which is responsible for controlling development [71], it
might facilitate assessment of toxicity in mammals. More comprehensive studies are
required to provide better understanding on the mechanistic pathways of DEHP- and
MEHP-induced toxic effects and to establish a correlation between zebrafish developmen-
tal toxicity and mammalian developmental toxicity that may facilitate further development
on risk assessment.
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